Getinge (OTCMKTS:GNGBY) Releases Quarterly Earnings Results

Getinge (OTCMKTS:GNGBYGet Free Report) posted its quarterly earnings results on Friday. The company reported $0.38 earnings per share for the quarter, Zacks reports. Getinge had a return on equity of 10.39% and a net margin of 6.92%.

Getinge Trading Up 11.4%

OTCMKTS GNGBY opened at $24.18 on Friday. The firm has a market cap of $6.59 billion, a PE ratio of 26.28 and a beta of 0.96. Getinge has a 1-year low of $18.99 and a 1-year high of $24.67. The company has a current ratio of 1.32, a quick ratio of 0.86 and a debt-to-equity ratio of 0.27. The stock has a 50-day moving average of $20.65 and a 200-day moving average of $21.34.

Analysts Set New Price Targets

Separately, Zacks Research raised Getinge to a “hold” rating in a research report on Thursday, April 23rd. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Get Our Latest Analysis on GNGBY

Getinge Company Profile

(Get Free Report)

Getinge AB is a global medical technology company that develops, manufactures and markets products and systems for hospitals and life sciences institutions. The company’s offerings focus on critical care, surgical workflows and infection control, aiming to improve clinical outcomes and operational efficiency. Getinge’s solutions support a range of applications from intensive care and cardiovascular treatments to sterile reprocessing of surgical instruments.

The company’s product portfolio includes sterilization and disinfection equipment, surgical tables and lights, ventilation systems, heart-lung machines and extracorporeal membrane oxygenation (ECMO) devices.

See Also

Earnings History for Getinge (OTCMKTS:GNGBY)

Receive News & Ratings for Getinge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Getinge and related companies with MarketBeat.com's FREE daily email newsletter.